Cover Image

Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

BACKGROUND: To evaluate long-term outcome of myeloablative allogeneic stem cell transplantation (allo-SCT) (MAC) versus reduced-intensity allo-SCT (RIC) in patients with relapsed/refractory Hodgkin's lymphoma (HL) in recent years. - PATIENTS AND METHODS: A total of 312 patients (63 MAC and 249...

Full description

Saved in:
Bibliographic Details
Main Authors: Genadieva-Stavrik, Sonja (Author) , Boumendil, A. (Author) , Dreger, Peter (Author) , Peggs, K. (Author) , Briones, J. (Author) , Corradini, P. (Author) , Bacigalupo, A. (Author) , Socié, G. (Author) , Bonifazi, F. (Author) , Finel, H. (Author) , Velardi, A. (Author) , Potter, M. (Author) , Bruno, B. (Author) , Castagna, L. (Author) , Malladi, R. (Author) , Russell, N. (Author) , Sureda, A. (Author)
Format: Article (Journal)
Language:English
Published: 29 August 2016
In: Annals of oncology
Year: 2016, Volume: 27, Issue: 12, Pages: 2251-2257
ISSN:1569-8041
Online Access: Get full text
Author Notes:S. Genadieva-Stavrik, A. Boumendil, P. Dreger, K. Peggs, J. Briones, P. Corradini, A. Bacigalupo, G. Socié, F. Bonifazi, H. Finel, A. Velardi, M. Potter, B. Bruno, L. Castagna, R. Malladi, N. Russell and A. Sureda
Description
Summary:BACKGROUND: To evaluate long-term outcome of myeloablative allogeneic stem cell transplantation (allo-SCT) (MAC) versus reduced-intensity allo-SCT (RIC) in patients with relapsed/refractory Hodgkin's lymphoma (HL) in recent years. - PATIENTS AND METHODS: A total of 312 patients (63 MAC and 249 RIC) with relapsed/refractory HL who received allo-SCT between 2006 and 2010 and were reported to the EBMT Database were included in the study. - RESULTS: With a median follow-up for alive patients of 56 (26-73) months, there were no significant differences in non-relapse mortality (NRM) between MAC and RIC. Relapse rate (RR) was somewhat lower in the MAC group (41% versus 52% at 24 months, P = 0.16). This lower RR translated into a marginal improvement in event-free survival (EFS) for the MAC group (48% versus 36% at 24 months, P = 0.09) with no significant differences in overall survival (73% for MAC and 62% for RIC at 24 months, P = 0.13). Multivariate analysis after adjusting for disease status at the time of allo-SCT showed that the use of MAC was of borderline statistical significance for predicting a lower RR and EFS [HR 0.7, 95% CI (0.5-1.0), P = 0.1] and [HR 0.7, 95% CI (0.5-1.0), P = 0.07], respectively, after allo-SCT. - CONCLUSIONS: With modern transplant practices, the NRM associated with MAC for HL has strongly decreased, resulting into non-significant improvement of EFS because of a somewhat better disease control compared with RIC transplants. The intensity of conditioning regimens should be considered when designing individual allo-SCT strategies or clinical trials in patients with relapsed/refractory HL.
Item Description:Gesehen am 02.06.2020
Physical Description:Online Resource
ISSN:1569-8041

Similar Items